JP2005523730A5 - - Google Patents

Download PDF

Info

Publication number
JP2005523730A5
JP2005523730A5 JP2004514868A JP2004514868A JP2005523730A5 JP 2005523730 A5 JP2005523730 A5 JP 2005523730A5 JP 2004514868 A JP2004514868 A JP 2004514868A JP 2004514868 A JP2004514868 A JP 2004514868A JP 2005523730 A5 JP2005523730 A5 JP 2005523730A5
Authority
JP
Japan
Prior art keywords
serotype
adenovirus
cells
cell line
subgroup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004514868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523730A (ja
JP4495588B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/050126 external-priority patent/WO2004001032A2/en
Publication of JP2005523730A publication Critical patent/JP2005523730A/ja
Publication of JP2005523730A5 publication Critical patent/JP2005523730A5/ja
Application granted granted Critical
Publication of JP4495588B2 publication Critical patent/JP4495588B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004514868A 2002-04-25 2003-04-24 安定なアデノウイルスベクターおよびその増殖方法 Expired - Lifetime JP4495588B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NL0200281 2002-04-25
NL0200656 2002-10-15
EP02102631 2002-11-25
PCT/EP2003/050126 WO2004001032A2 (en) 2002-04-25 2003-04-24 Stable adenoviral vectors and methods for propagation thereof

Publications (3)

Publication Number Publication Date
JP2005523730A JP2005523730A (ja) 2005-08-11
JP2005523730A5 true JP2005523730A5 (enExample) 2010-05-06
JP4495588B2 JP4495588B2 (ja) 2010-07-07

Family

ID=34068720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004514868A Expired - Lifetime JP4495588B2 (ja) 2002-04-25 2003-04-24 安定なアデノウイルスベクターおよびその増殖方法

Country Status (17)

Country Link
US (2) US7285265B2 (enExample)
EP (1) EP1497440B1 (enExample)
JP (1) JP4495588B2 (enExample)
KR (1) KR101006594B1 (enExample)
CN (1) CN100374574C (enExample)
AT (1) ATE405663T1 (enExample)
AU (1) AU2003271738C1 (enExample)
CA (1) CA2478508C (enExample)
DE (1) DE60323080D1 (enExample)
DK (1) DK1497440T3 (enExample)
ES (1) ES2310247T3 (enExample)
IL (1) IL164802A0 (enExample)
NO (1) NO334299B1 (enExample)
NZ (1) NZ534865A (enExample)
PL (1) PL208588B1 (enExample)
SI (1) SI1497440T1 (enExample)
WO (1) WO2004001032A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
ES2335657T3 (es) * 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
CN1655827B (zh) 2002-05-27 2010-06-23 佩尔·松内·霍尔姆 腺病毒和编码其的核酸的新应用
EP1539937A4 (en) * 2002-08-22 2006-07-26 Merck & Co Inc METHOD FOR THE REPRODUCTION OF ADENOVIRUS AND PRODUCT VIRUS THEREWITH
CA2527369A1 (en) * 2003-07-18 2005-02-03 Onyx Pharmaceuticals, Inc. Subgroup b adenoviral vectors for treating disease
WO2005051430A1 (de) 2003-11-14 2005-06-09 Per Sonne Holm Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
NZ555907A (en) 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
EP1830864A2 (de) * 2004-12-31 2007-09-12 Per Sonne Holm E1 -minus adenoviren und deren verwendung
AU2006203736B2 (en) * 2004-12-31 2012-03-29 Per Sonne Holm Method for reversing multiple resistance in animal cells
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
KR20080052512A (ko) * 2005-05-23 2008-06-11 박신, 인크. 아데노바이러스-무함유 재조합 아데노바이러스 벡터의 급속생산
EP1998804B1 (en) * 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
BRPI0720219A2 (pt) 2006-12-08 2013-12-24 Univ Iowa State Res Found Inc Genes de planta envolvidos em absorção e metabolismo de nitrato
CA2742474C (en) 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
PT2358757T (pt) 2008-11-18 2018-12-04 Beth Israel Deaconess Medical Ct Inc Vacinas antivirais com imunogenicidade celular melhorada
NZ598000A (en) 2009-08-07 2013-10-25 Transgene Sa Composition for treating hbv infection
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
CN103370411B (zh) 2010-12-14 2016-05-04 美国卫生和人类服务部 腺病毒血清型26和血清型35线状病毒疫苗
MY170927A (en) 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
ES2663688T3 (es) * 2012-07-04 2018-04-16 Sirion Biotech Gmbh Medios y métodos para aumentar la producción de adenovirus
CN105051198A (zh) * 2012-11-16 2015-11-11 貝丝以色列女执事医疗中心 重组腺病毒及其用途
SG11201508567XA (en) 2013-04-25 2015-11-27 Crucell Holland Bv Stabilized soluble prefusion rsv f polypeptides
JP2017527564A (ja) 2014-09-03 2017-09-21 バヴァリアン ノルディック エー／エス 免疫応答の増進を目的とする方法及び組成物
CN107454848B (zh) 2014-09-03 2021-06-22 巴法里安诺迪克有限公司 用于诱导针对丝状病毒感染的保护性免疫的方法和组合物
CA2961024A1 (en) 2014-09-26 2016-03-31 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
TWI710635B (zh) * 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
CN107466324B (zh) 2015-04-14 2022-01-14 扬森疫苗与预防公司 具有双向启动子的表达两种转基因的重组腺病毒
WO2016187613A1 (en) 2015-05-21 2016-11-24 Janssen Vaccines & Prevention B.V Methods and compositions for inducing protective immunity against filovirus infection and/or disease
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
CA3008542C (en) 2015-12-15 2020-06-02 Janssen Vaccines & Prevention B.V. Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
EP3808374A1 (en) 2016-04-05 2021-04-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f proteins for use in the prophylaxis of rsv infection
CN109069612A (zh) 2016-04-05 2018-12-21 扬森疫苗与预防公司 针对rsv的疫苗
BR112018072865A2 (pt) 2016-05-12 2019-04-30 Janssen Vaccines & Prevention B.V. promotor bidirecional potente e equilibrado
PE20190110A1 (es) 2016-05-30 2019-01-15 Janssen Vaccines And Prevention B V Proteinas f de prefusion del vrs estabilizadas
JP6595132B2 (ja) 2016-06-16 2019-10-23 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｉｖワクチン製剤
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3484506A1 (en) 2016-07-14 2019-05-22 Janssen Vaccines & Prevention B.V. Hpv vaccines
US10925955B2 (en) 2016-07-15 2021-02-23 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a Marburg virus infection
WO2018011768A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
WO2018075559A1 (en) 2016-10-17 2018-04-26 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CN110268061B (zh) 2017-02-09 2024-07-16 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
US11173204B2 (en) 2017-04-06 2021-11-16 Janssen Vaccines & Prevention B.V. MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3638302B1 (en) 2017-06-15 2024-03-13 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding hiv antigens, and methods of use thereof
BR112020001052A2 (pt) 2017-07-28 2020-09-08 Janssen Vaccines & Prevention B.V. métodos e composições para imunizações heterólogas com reprna
BR112020004143A2 (pt) 2017-09-15 2020-09-01 Janssen Vaccines & Prevention B.V. método para a indução segura de imunidade contra vírus sincicial respiratório (rsv)
EP3713599A1 (en) 2017-11-20 2020-09-30 Janssen Pharmaceuticals, Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
WO2019118480A1 (en) 2017-12-11 2019-06-20 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
MX2020006471A (es) 2017-12-19 2020-09-22 Janssen Sciences Ireland Unlimited Co Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
JP7653013B2 (ja) 2018-01-04 2025-03-28 アイコニック セラピューティクス リミテッド ライアビリティ カンパニー 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
EP3810277A1 (en) 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
PH12021550974A1 (en) 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
JP2022532723A (ja) 2019-05-15 2022-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー 季節性インフルエンザワクチン及びアデノウイルス系呼吸器合胞体ウイルスワクチンの共投与
AU2020275910A1 (en) 2019-05-15 2021-11-04 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CN110714027A (zh) * 2019-10-28 2020-01-21 嘉铭(固安)生物科技有限公司 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
PH12023550030A1 (en) 2020-07-08 2024-03-11 Janssen Sciences Ireland Unlimited Co Rna replicon vaccines against hbv
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
CN117821405B (zh) * 2023-11-24 2024-11-26 广州医科大学 基因嵌合型人腺病毒及其构建方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5922315A (en) 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
IL132673A0 (en) 1997-05-08 2001-03-19 Genetic Therapy Inc Gene transfer with adenoviruses having modified fiber proteins
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
JP4683727B2 (ja) 1999-03-04 2011-05-18 クルーセル ホランド ベスローテン フェンノートシャップ 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法
EP1816204B1 (en) 1999-05-17 2010-10-20 Crucell Holland B.V. Recombinant Adenovirus of the Ad26 serotype
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6365394B1 (en) * 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
DE10045687B4 (de) * 2000-09-15 2006-07-06 MICROMUN Privates Institut für Mikrobiologische Forschung GmbH Biotechnikum Greifswald Expressionskassetten und Adenovirusvektoren
WO2002024730A2 (en) 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
EP1348030B1 (en) 2001-01-04 2009-11-25 Wadell, Göran Viral vector for gene therapy
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.

Similar Documents

Publication Publication Date Title
JP2005523730A5 (enExample)
Gao et al. State‐of‐the‐art human adenovirus vectorology for therapeutic approaches
Trowitzsch et al. New baculovirus expression tools for recombinant protein complex production
Vellinga et al. Challenges in manufacturing adenoviral vectors for global vaccine product deployment
Havenga et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER. C6 cells
Schiedner et al. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production
Gao et al. Human adenovirus type 35: nucleotide sequence and vector development
Ansorge et al. Development of a scalable process for high‐yield lentiviral vector production by transient transfection of HEK293 suspension cultures
Kamen et al. Development and optimization of an adenovirus production process
Zhang et al. Role for the adenovirus IVa2 protein in packaging of viral DNA
Danthinne et al. Production of first generation adenovirus vectors: a review
EP0705344B1 (en) Adenovirus vectors for gene therapy
Vogels et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity
Ostapchuk et al. Control of adenovirus packaging
EP3658668B1 (en) Adenoviral vectors
Mizuguchi et al. Approaches for generating recombinant adenovirus vectors
CA2477954A1 (en) Means and methods for the production of adenovirus vectors
CA2428739A1 (en) Complementing cell lines
JP2003514526A5 (enExample)
JP5986381B2 (ja) ベクター
Ostapchuk et al. Characterization of Empty adenovirus particles assembled in the absence of a functional adenovirus IVa2 protein
EP0809704B1 (fr) Procede de preparation de genome d'adenovirus recombinants
Choi et al. AdHTS: a high-throughput system for generating recombinant adenoviruses
Doerfler A new concept in (adenoviral) oncogenesis: integration of foreign DNA and its consequences
Carina Silva et al. Adenovirus vector production and purification